The DOI matches its Crossref record.
Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, Aldafermin (NGM282) did not reach statistical significance in histological improvement of liver fibrosis in NASH patients, even if a promising reduction in fibrosis stage and biomarkers of fibrogenesis were reported at the clinical trials interim analysis.[77,78]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [78]
In the citing paper
“However, Aldafermin (NGM282) did not reach statistical significance in histological improvement of liver fibrosis in NASH patients, even if a promising reduction in fibrosis stage and biomarkers of fibrogenesis were reported at the clinical trials interim analysis.[77,78]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [77]
Citations
Cites
Still being checked.
Cited by
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Metadata
- Authors
- Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., Kohli, A., Nelson, K., Gottwald, M., Chang, W., Yan, A., Depaoli, A., Ling, L., & Lieu, H.
- Affiliations
- University of Oxford (GB)
- Duke University (US)
- Brooke Army Medical Center (US)
- Gastro One (United States) (US)
- Texas Digestive Disease Consultants (US)
- Pinnacle Clinical Research (US)
- Adobe Gastroenterology (US)
- Institute for Liver Health (US)
- NGM Biopharmaceuticals (United States) (US)
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 73
- Pages
- S114-S115
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4235586441
- Cited by
- 1
- References
- 0
- Citations by year
- 2021: 1
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Keywords
- nonalcoholic steatohepatitis, liver regeneration, hepatocyte cell cycle, CDK1, hepatocyte hypertrophy, hepatic progenitor cells, cholangiocytes, HNF4α, liver fibrosis, liver inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1016/s0168-8278(20)30750-9
- The paper
- Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., Kohli, A., Nelson, K., Gottwald, M., Chang, W., Yan, A., Depaoli, A., Ling, L., & Lieu, H. (2020). Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(20)30750-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.